相关实验视频

Updated: Jan 16, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

对于乳腺癌患者的更年期激素治疗:目前的证据是什么?

Sarah Glynne¹, James Simon^2,3, Anthony Branson⁴

¹Portland Hospital, London, UK.

Menopause (New York, N.Y.)

|September 30, 2025

概括

乳腺癌幸存者可以选择更年期激素治疗 (MHT) 来缓解症状,接受更高的复发风险. 分享决策对于个性化护理至关重要,平衡利益与潜在风险.

科学领域:

在瘤学瘤学.
妇科妇科妇科妇科
更年期管理管理

背景情况:

乳腺癌幸存者经常面临由于治疗引起的荷尔蒙缺乏症而具有挑战性的更年期症状.
这些幸存者的治疗选择有限,因为由于复发风险,传统的雌激素替代疗法是禁忌的.
在乳腺癌后使用更年期激素疗法 (MHT) 需要基于证据的指导意见至关重要.

研究的目的:

审查有关MHT在乳腺癌幸存者的使用现有证据.
建立一个共识声明,定义MHT在乳腺癌后的作用.
为了确定MHT和乳腺癌的未来研究的研究缺口.

主要方法:

一个由25名专家组成的多学科小组,包括瘤学家和更年期专家,使用了经过修改的Delphi方法.
证据审查侧重于阴道和全身MHT,以及乳腺癌的辅助内分泌疗法.
达成共识的陈述是基于≥70%的同意,由额外的乳腺癌专家进行同行评审.

主要成果:

专家小组得出结论,一些女性可能会选择MHT,接受增加复发风险以改善生活质量.
适度的证据支持MHT的使用,而高质量的证据证实了ER+乳腺癌抗雌激素治疗的好处.
共同决策至关重要,考虑到症状严重程度,生活质量影响,复发风险和患者偏好.

结论:

个性化更年期护理和共同决策对于考虑MHT的乳腺癌幸存者来说至关重要.
治疗选择应该平衡症状缓解,潜在的复发风险,以及患者特定的目标和偏好.
在临床试验中注册考虑MHT的患者,如MENO-ABC,强烈建议进行进一步研究.

关键词:

乳腺癌乳腺癌乳腺癌知情下做出选择的选择.绝经期的荷尔蒙治疗.更年期绝经绝经共享决策共同的决策

更多相关视频

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

相关概念视频

Menopause

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Hormonal Regulation of the Menstrual Cycle

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Hormonal Control of the Ovarian Cycle

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...